NEW LAUNCH: CarciVac®, vaccine onco BCG

28/09/2020

Bioprofarma Bagó presents CarciVac® for the treatment of non-muscle invasive bladder cancer. We are pleased to announce the launch of CarciVac® vaccine onco BCG Bacilo Calmette-Guérin. This product complements our Urology portfolio continuing our commitment to patients suffering bladder cancer.

CarciVac® is manufactured by Serum Institute of India, the world’s largest producer of vaccines, which allows us to guarantee the availability of the product in the market.

CarciVac® vaccine onco BCG Bacilo Calmette-Guérin is indicated for the treatment of:

  • Flat urothelial cell carcinoma in situ (CIS) of the bladder
  • As adjuvant treatment after TUR of primary or recurrent superficial papillary urothelial cell carcinoma (stage Ta and T1).

It is presented in a 40 mg lyophilized ampoule bottle for 3 vials.

For more information, please click here

 

XXVI Argentine and International Congress of Clinical Oncology organized by the AAOC

November 8-10, the XXVI Argentine and International Congress of Clinical Oncology 2023 was held at La Rural, in the City of Buenos Aires, and Bioprofarma Bago was there.

Read note

26th ARGENTINE CONGRESS OF HEMATOLOGY organized by the Argentine Society of Hematology

Bioprofarma Bagó participated in the 26th Argentine Congress of Hematology 2023, which was held from November 1st to the 4th at its two venues: the Sheraton Hotel and the Costa Galana Hotel, in the City of Mar del Plata.

Read note

New Product Launch VETRANO®palbociclib

We are thrilled to present to our community the launch of the product VETRANO® palbociclib, for our Oncology Line.

Read note